Hagens Berman Sobol Shapiro Investigations
Johnson & Johnson
Date Started: January 15, 2009
Hagens Berman is investigating claims whether pharmaceutical giant Johnson & Johnson (NYSE: JNJ) defrauded investors by not disclosing that some of its consumer products including Tylenol may be contaminated.
Reports claim Johnson & Johnson knew of the contamination issue, which is linked to health issues in some consumers, since 2008 but neglected to fully disclose the problem to shareholders and the general public until today after pressure by federal regulators.
Earlier today, Johnson & Johnson recalled several brands of over-the-counter products from store shelves including Tylenol, Motrin, Rolaids and Benadryl.
The U.S. Food and Drug Administration issued a Warning Letter to the company for failing to disclose in September 2009 contamination of the products by 2,4,6-tirbromoanisole (TBA), a chemical used as a fungicide, wood preservative and flame retardant. Johnson & Johnson has admitted that the effects of TBA on humans have not been heavily studied. Consumers using the TBA-affected products have reported nausea, vomiting, and diarrhea.
The firm is interested in talking with those who have first-hand knowledge of the issue.
Investors that purchased stock in Johnson & Johnson after Sept. 1, 2009 can contact Reed K. Kathrein with Hagens Berman Sobol Shapiro at
